News · 26 weeks121+29%
2025-12-072026-05-31
Mix3990d
- Insider14(36%)
- Other12(31%)
- SEC Filings10(26%)
- Leadership1(3%)
- Dividends1(3%)
- M&A1(3%)
Latest news
25 items- PRLabcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal CancerCollaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family membersResearch will also assess the clinical impact of broader genetic testing in colorectal cancer careBURLINGTON, N.C., May 29, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the Alliance for Clinical Trials in Oncology to advance a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer (CRC). The trial will evaluate approaches to increase germline genetic testing among at-risk family members, as well as the
- PRLabcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side EffectsNew pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Pathology to support safer, more personalized cancer treatmentBURLINGTON, N.C., May 28, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of its expanded DPYD Genotyping test to help identify cancer patients who may be at increased risk for severe or life-threatening side effects from fluoropyrimidine chemotherapy. Labcorp now offers genotype testing for all DPYD Tier 1 and Tier 2 variants recommended by the Association for Molecular Pathology (AMP).
- SECLabcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
- PRLabcorp to Present at the Jefferies Global Healthcare ConferenceBURLINGTON, N.C., May 27, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, from 12:15 pm to 12:45 pm ET. The presentation can be accessed via a live webcast on the Labcorp Investor Relations website at ir.labcorp.com. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 90 days following the event.About LabcorpLa
- SECLabcorp Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
- SECSEC Form SD filed by Labcorp Holdings Inc.SD - LABCORP HOLDINGS INC. (0000920148) (Filer)
- PRLabcorp Launches MyLabcorp™, a New AI-Powered Mobile App Designed to Help Consumers Understand Lab Results and Track Health Trends Over TimeMyLabcorp connects lab results, educational content and AI-enabled features in a secure, personalized mobile experience Leverages OpenAI models designed to help users understand their results, ask questions and identify patterns over timeBURLINGTON, N.C., May 20, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of MyLabcorp™, an AI-powered mobile app that brings together lab results, AI-enabled features and clinical guideline-based content in a secure, personalized mobile experience. The app is designed to give users additional context about their health and support more informed conversations with healthc
- INSIDERPresident & CEO Schechter Adam H sold $1,502,314 worth of shares (5,903 units at $254.50) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 107,234 units (SEC Form 4)4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- PRLabcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health SystemsLabcorp's full test menu will be available through Epic's Aura platformIntegration builds on the successful deployment of Invitae genetic testing and accelerates access to the latest genetic and specialty diagnostics through AuraCollaboration will help reduce IT complexity, streamline lab ordering and improve access to diagnostic innovation for hospitals and health systems using Epic nationwideBURLINGTON, N.C., May 12, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with Epic, the nation's leading electronic health record (EHR) supporting hospitals and health systems. Through the collaborat
- SECSEC Form 144 filed by Labcorp Holdings Inc.144 - LABCORP HOLDINGS INC. (0000920148) (Subject)
- SECSEC Form 10-Q filed by Labcorp Holdings Inc.10-Q - LABCORP HOLDINGS INC. (0000920148) (Filer)
- SECLabcorp Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
- PRLabcorp Announces 2026 First Quarter Results; Raises Full Year 2026 GuidanceResults from Operations for first quarter 2026 versus first quarter 2025:Revenue: $3.54 billion vs. $3.35 billion, up 5.8%Diluted EPS: $3.35 vs. $2.52, up 32.8%Adjusted EPS: $4.25 vs. $3.84, up 10.6%Raised Full-Year Enterprise Revenue and Adjusted EPS guidance:Revenue guidance of 5.0% to 6.1%; up 20 basis points at the midpointAdjusted EPS range of $17.70 to $18.35; up 13 cents at the midpointAdvanced leadership in specialty and companion diagnostics and expanded strategic health systems collaborationsCollaborated with Optum.ai to enhance patient and provider experienceBURLINGTON, N.C., April 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc (NYSE:LH), a global leader of innovative and comprehen
- PRLabcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®BURLINGTON, N.C., April 22, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the U.S. Food and Drug Administration (FDA) to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck's KEYTRUDA®.i KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) are the first FDA-approved PD-1 inhibitors available as part of a complete treatment regimen for eligible patients with platinum-resistant ovarian cancer.ii
- PRLabcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 MinutesFirst FDA-cleared rapid fentanyl test of its kind made in the United States designed to help emergency department and hospital teams act quickly when every second countsFentanyl Urine Visual Test is available through Labcorp Point of Care, previously known as MEDTOX DiagnosticsBURLINGTON, N.C., April 15, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of the Labcorp Fentanyl Urine Visual Test, the first U.S. Food and Drug Administration (FDA)-cleared rapid fentanyl test of its kind manufactured in the United States. The test delivers results in just 10 minutes, giving healthcare providers fast, actionable
- PRLabcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's ResearchPlatform leverages agentic AI and diverse healthcare datasets to transform and speed drug developmentBURLINGTON, N.C., April 14, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced a new AI-powered real-world data platform, designed to help researchers and biopharmaceutical companies analyze Alzheimer's disease-related data faster. Developed with Amazon Web Services (AWS) and Datavant, the platform provides access to large, diverse datasets and advanced analytics—using deidentified, privacy-protected healthcare data—designed to accelerate scientific discovery, shorten drug development timelines and improve identificatio
- SECSEC Form DEFA14A filed by Labcorp Holdings Inc.DEFA14A - LABCORP HOLDINGS INC. (0000920148) (Filer)
- SECSEC Form DEF 14A filed by Labcorp Holdings Inc.DEF 14A - LABCORP HOLDINGS INC. (0000920148) (Filer)
- SECLabcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
- PRLabcorp Declares Quarterly DividendBURLINGTON, N.C., April 9, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 11, 2026, to stockholders of record as of the close of business on May 29, 2026. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident
- SECLabcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
- PRLabcorp to Announce First Quarter Financial Results on April 30, 2026BURLINGTON, N.C., March 31, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2026 before the market opens on Thursday, April 30, 2026. The company will host a webcast beginning at 9:00 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the "News & Events" section of the Labcorp Investor Relations website at https://ir.labcorp.com. A link to the earnings webcast will also be available on the investor relations website.
- INSIDERSEC Form 4 filed by Schechter Adam H4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- INSIDERSEC Form 4 filed by Graham Anita Z4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- INSIDERSEC Form 4 filed by Schroeder Mark S4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
LH FAQ
6 questionsWhat does Labcorp Holdings Inc. do?
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based...Where does LH stock trade?
Labcorp Holdings Inc. (LH) is listed on NYSE.What sector and industry is LH in?
Labcorp Holdings Inc. operates in the Health Care sector, Medical Specialities industry.What are analysts saying about LH?
Labcorp Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from HSBC Securities: Hold on 2025-07-10.What companies are similar to LH?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare LH side-by-side with any of them on Quantisnow.How can I track LH on Quantisnow?
Quantisnow aggregates Labcorp Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LH to receive live email and push alerts on every new disclosure.